Latest Resapp deal could turn 6 minutes into $6m plus a year.

The average GP consultation take about six minutes.

That figure is very significant in the context of the two-year, non-exclusive commercial software licensing agreement Resapp Health [ASX:RAP] has just signed with Phenix Health Pty Ltd.

Phenix Health Pty Ltd is an integrative medical tech company founded in 2015 as a spin-off from

its Australia-wide after-hours home visit doctor service.

Resapp has granted Phenix a two year software license that generates between $5 and $10 per use of Resapp's smartphone app which essentially diagnoses a range of respiratory illnesses by having the patient cough into the phone. The app then sends the results to the doctor's screen during a tele-health consultation.

This morning I did a very conservative guesstimate of what the deal could mean for Resapp, based on the industry-accepted consultation time of six minutes and combining it with Phenix's 300 tele-health doctors.

In an hour, a GP could see roughly five or six patients.

In an eight hour day conservatively that equates to about 35 patients a day.

On average half of the patients a GP sees has a respiratory issue.

So that means that conservatively 15 patients a day might use Resapp's software which translates into $75 in licensing income per doctor.

Crunch that forward by the 300 doctors and over a year, the license fees could be close to six million dollars.

I spoke with Dr Tony Keating, CEO of Resapp in a previous post and you can listen to that interview below.

ASX Announcement

02244865.pdf

Download PDF • 116KB

DISCLAIMER AND IMPORTANT INFORMATION

I own shares in this company at the time of writing this post. However I do not accept any payment from this or any other company I cover. Nor is my interview or blog in any way a recommendation and should not be seen as a form of financial advice. Disruptive technology stocks should be considered very speculative, high-risk, and extremely volatile. There are significant risks inherent in developing new technologies that are not discussed here. You should always seek professional advice before considering any share purchase or sale. Please read our full disclaimer.